S&P 500   5,098.57 (-0.63%)
DOW   38,816.90 (-0.44%)
QQQ   438.58 (-1.23%)
AAPL   170.43 (-2.67%)
MSFT   406.75 (-1.97%)
META   493.74 (-0.89%)
GOOGL   132.07 (-0.96%)
AMZN   175.79 (-1.01%)
TSLA   184.27 (-2.06%)
NVDA   853.79 (+0.17%)
NIO   5.52 (+3.56%)
AMD   203.78 (-0.77%)
BABA   72.55 (+0.76%)
T   17.23 (+2.56%)
F   12.73 (-0.08%)
MU   94.96 (-0.85%)
CGC   2.95 (-2.32%)
GE   161.76 (+0.47%)
DIS   113.68 (+-0.01%)
AMC   4.35 (+0.69%)
PFE   25.85 (-0.15%)
PYPL   59.90 (-0.13%)
XOM   105.64 (+1.23%)
S&P 500   5,098.57 (-0.63%)
DOW   38,816.90 (-0.44%)
QQQ   438.58 (-1.23%)
AAPL   170.43 (-2.67%)
MSFT   406.75 (-1.97%)
META   493.74 (-0.89%)
GOOGL   132.07 (-0.96%)
AMZN   175.79 (-1.01%)
TSLA   184.27 (-2.06%)
NVDA   853.79 (+0.17%)
NIO   5.52 (+3.56%)
AMD   203.78 (-0.77%)
BABA   72.55 (+0.76%)
T   17.23 (+2.56%)
F   12.73 (-0.08%)
MU   94.96 (-0.85%)
CGC   2.95 (-2.32%)
GE   161.76 (+0.47%)
DIS   113.68 (+-0.01%)
AMC   4.35 (+0.69%)
PFE   25.85 (-0.15%)
PYPL   59.90 (-0.13%)
XOM   105.64 (+1.23%)
S&P 500   5,098.57 (-0.63%)
DOW   38,816.90 (-0.44%)
QQQ   438.58 (-1.23%)
AAPL   170.43 (-2.67%)
MSFT   406.75 (-1.97%)
META   493.74 (-0.89%)
GOOGL   132.07 (-0.96%)
AMZN   175.79 (-1.01%)
TSLA   184.27 (-2.06%)
NVDA   853.79 (+0.17%)
NIO   5.52 (+3.56%)
AMD   203.78 (-0.77%)
BABA   72.55 (+0.76%)
T   17.23 (+2.56%)
F   12.73 (-0.08%)
MU   94.96 (-0.85%)
CGC   2.95 (-2.32%)
GE   161.76 (+0.47%)
DIS   113.68 (+-0.01%)
AMC   4.35 (+0.69%)
PFE   25.85 (-0.15%)
PYPL   59.90 (-0.13%)
XOM   105.64 (+1.23%)
S&P 500   5,098.57 (-0.63%)
DOW   38,816.90 (-0.44%)
QQQ   438.58 (-1.23%)
AAPL   170.43 (-2.67%)
MSFT   406.75 (-1.97%)
META   493.74 (-0.89%)
GOOGL   132.07 (-0.96%)
AMZN   175.79 (-1.01%)
TSLA   184.27 (-2.06%)
NVDA   853.79 (+0.17%)
NIO   5.52 (+3.56%)
AMD   203.78 (-0.77%)
BABA   72.55 (+0.76%)
T   17.23 (+2.56%)
F   12.73 (-0.08%)
MU   94.96 (-0.85%)
CGC   2.95 (-2.32%)
GE   161.76 (+0.47%)
DIS   113.68 (+-0.01%)
AMC   4.35 (+0.69%)
PFE   25.85 (-0.15%)
PYPL   59.90 (-0.13%)
XOM   105.64 (+1.23%)
NASDAQ:ADIL

Adial Pharmaceuticals (ADIL) Stock Price, News & Analysis

$2.42
-0.33 (-12.00%)
(As of 10:04 AM ET)
Today's Range
$2.29
$2.82
50-Day Range
$0.83
$3.26
52-Week Range
$0.76
$15.00
Volume
377,462 shs
Average Volume
5.37 million shs
Market Capitalization
$4.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Adial Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Bearish
11.48% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.56mentions of Adial Pharmaceuticals in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($4.40) to ($1.46) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.53 out of 5 stars


ADIL stock logo

About Adial Pharmaceuticals Stock (NASDAQ:ADIL)

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

ADIL Stock Price History

ADIL Stock News Headlines

Detecting Cancer in Mere Seconds: Early Investment Opportunity
A revolutionary cancer diagnostic tool is likely to come to fruition with anticipated FDA approval expected in just months. With the ability to detect cancer's "molecular fingerprint" in just seconds, it also offers far superior accuracy to current detection methods and reduces the need for invasive biopsies.
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Update
Detecting Cancer in Mere Seconds: Early Investment Opportunity
A revolutionary cancer diagnostic tool is likely to come to fruition with anticipated FDA approval expected in just months. With the ability to detect cancer's "molecular fingerprint" in just seconds, it also offers far superior accuracy to current detection methods and reduces the need for invasive biopsies.
Adial Pharmaceuticals reports Q3 results
See More Headlines
Receive ADIL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adial Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/11/2021
Today
3/05/2024
Next Earnings (Estimated)
4/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ADIL
Fax
N/A
Employees
16
Year Founded
N/A

Profitability

Net Income
$-12,730,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.17 per share

Miscellaneous

Free Float
1,422,000
Market Cap
$4.57 million
Optionable
Optionable
Beta
1.52
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Cary John Claiborne MBA (Age 64)
    CEO, President & Director
    Comp: $415.08k
  • Mr. Joseph A. M. Truluck M.B.A. (Age 46)
    MBA, CFO, Treasurer & Secretary
    Comp: $279.7k
  • Mr. Tony Goodman (Age 60)
    COO & Director
    Comp: $59k
  • Dr. Bankole A. Johnson DSc (Age 64)
    FRCPsych, M.D., M.Phil, Ph.D., Founder & Chief Medical Officer
    Comp: $375k
  • Mr. John R. Martin J.D.
    General Counsel
  • Mr. Alex Lugovoy
    Chief Business Officer
  • Dr. Jack W. Reich Ph.D. (Age 75)
    Head of Regulatory
    Comp: $17.01k
  • Mr. Mark H. Peikin
    Chief Strategy Officer & Chief Development Officer
  • Ms. Catherine Fratila
    Controller














ADIL Stock Analysis - Frequently Asked Questions

How have ADIL shares performed in 2024?

Adial Pharmaceuticals' stock was trading at $1.86 on January 1st, 2024. Since then, ADIL shares have increased by 31.2% and is now trading at $2.44.
View the best growth stocks for 2024 here
.

Are investors shorting Adial Pharmaceuticals?

Adial Pharmaceuticals saw a increase in short interest during the month of February. As of February 15th, there was short interest totaling 173,300 shares, an increase of 691.3% from the January 31st total of 21,900 shares. Based on an average daily trading volume, of 292,100 shares, the short-interest ratio is presently 0.6 days. Currently, 11.5% of the company's shares are sold short.
View Adial Pharmaceuticals' Short Interest
.

When is Adial Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our ADIL earnings forecast
.

How were Adial Pharmaceuticals' earnings last quarter?

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) issued its quarterly earnings data on Wednesday, August, 11th. The company reported ($6.25) earnings per share for the quarter, missing analysts' consensus estimates of ($5.00) by $1.25.

When did Adial Pharmaceuticals' stock split?

Shares of Adial Pharmaceuticals reverse split on Monday, August 7th 2023. The 1-25 reverse split was announced on Monday, August 7th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of Adial Pharmaceuticals own?
When did Adial Pharmaceuticals IPO?

(ADIL) raised $8 million in an initial public offering on Friday, July 27th 2018. The company issued 1,500,000 shares at a price of $5.00 per share. Joseph Gunnar & Co. served as the underwriter for the IPO and Dawson James Securities was co-manager.

Who are Adial Pharmaceuticals' major shareholders?

Adial Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Armistice Capital LLC (9.58%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bankole A Johnson, James W Jr Newman, Kevin Schuyler and William B Stilley III.
View institutional ownership trends
.

How do I buy shares of Adial Pharmaceuticals?

Shares of ADIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ADIL) was last updated on 3/5/2024 by MarketBeat.com Staff